Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 85

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Facioscapulohumeral muscular dystrophy

Not recruiting

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Losmapimod
  • Sponsor:Fulcrum Therapeutics Inc.

Duchenne muscular dystrophy+1

Not recruiting

Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:F. Hoffmann-La Roche AG

Glycogen storage disease type II

Not recruiting

Long-Term Safety Study of Avalglucosidase Alfa for Patients with Pompe Disease in France

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi Winthrop Industrie

Insomnia

Not recruiting

Study on Neurexan for Improving Sleep in Patients with Short-Term Insomnia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Biologische Heilmittel Heel GmbH

Subarachnoid haemorrhage

Not recruiting

Study on the Effects of Nadroparin Calcium in Patients with Subarachnoid Hemorrhage

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nadroparin Calcium
  • Sponsor:Amsterdam UMC Stichting

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Spinal muscular atrophy

Not recruiting

Long-term Safety Study of Onasemnogene Abeparvovec for Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Onasemnogene Abeparvovec
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

Study on Frexalimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Amyotrophic lateral sclerosis+2

Not recruiting

Study of Tofersen for Adults with Presymptomatic Amyotrophic Lateral Sclerosis (ALS) Due to SOD1 Gene Mutation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tofersen
  • Sponsor:Biogen Idec Research Limited

Cluster headache

Not recruiting

Study on Repeated Corticosteroid Injections with Methylprednisolone Acetate and Sodium Chloride for Patients with Chronic Cluster Headache

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Leiden University Medical Center

Narcolepsy

Not recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Neuroblastoma

Not recruiting

Study of LY3295668 Erbumine for Patients with Relapsed or Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:(2R,4R)-1-(3-Chloro-2-Fluorobenzyl)-4-((3-Fluoro-6-((5-Methyl-1H-Pyrazol-3-Yl)Amino)Pyridin-2-Yl)Methyl)-2-Methylpiperidine-4-Carboxylic Acid
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.